60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · Real-Time Price · USD
0.920
0.00 (0.01%)
Nov 20, 2024, 4:00 PM EST - Market closed
SXTP Revenue
60 Degrees Pharmaceuticals had revenue of $148.11K in the quarter ending September 30, 2024, with 16.85% growth. This brings the company's revenue in the last twelve months to $462.61K, up 128.99% year-over-year. In the year 2023, 60 Degrees Pharmaceuticals had annual revenue of $253.57K, down -50.40%.
Revenue (ttm)
$462.61K
Revenue Growth
+128.99%
P/S Ratio
2.38
Revenue / Employee
$154,204
Employees
3
Market Cap
1.71M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 253.57K | -257.64K | -50.40% |
Dec 31, 2022 | 511.21K | -5.84M | -91.95% |
Dec 31, 2021 | 6.35M | 3.80M | 149.18% |
Dec 31, 2020 | 2.55M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSXTP News
- 6 days ago - 60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results - GlobeNewsWire
- 6 weeks ago - 60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch - GlobeNewsWire
- 2 months ago - Hyliion Holdings And 2 Other Stocks Under $5 Executives Are Buying - Benzinga
- 2 months ago - 60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 3 months ago - 60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 3 months ago - 60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results - GlobeNewsWire
- 3 months ago - 60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study - GlobeNewsWire
- 3 months ago - 60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split - GlobeNewsWire